If you take extra vitamin D to protect your bones as you age, a new five-year randomized trial from Finland has an uncomfortable message: in older adults who already had decent vitamin D levels, higher doses did not prevent fractures. One dose group actually had more fractures than placebo. Before you panic or toss your bottle, here is what the study found and how to read it.
The Study: Who, What and How Long
The Finnish Vitamin D Trial (FIND), published in the journal Bone in 2026, was led by researchers at the University of Eastern Finland. Co-authors include JoAnn Manson of Harvard, who is well known for large vitamin D trials.
- Design: randomized, placebo-controlled trial (ClinicalTrials.gov NCT01463813)
- Participants: 2,495 older adults, men aged 60 or older and women aged 65 or older
- Groups: 1,600 IU/day of vitamin D3, 3,200 IU/day of vitamin D3, or placebo
- Duration: randomized for 5 years, with a mean supplementation period of 4.1 years and extended follow-up of 7.3 years
- Outcome: fractures, identified through two national care notification registers
Using national registers means fractures were not missed because participants skipped a clinic visit. It also means the data come from diagnosis records rather than from systematic imaging.
The Headline Result: No Protection
Neither dose reduced fracture risk. During the supplementation period, there were 49 fractures in the placebo group, 73 in the 1,600 IU group and 52 in the 3,200 IU group.
Over the extended 7.3-year follow-up, the counts were 104 (placebo), 139 (1,600 IU) and 111 (3,200 IU). The authors found no statistically significant differences in fracture subtypes. Age, sex, BMI, prior fracture or falls, an osteoporosis diagnosis, and calcium supplement use did not change the picture.
The authors concluded that the findings "do not support use of high vitamin D doses for fracture prevention" in a largely vitamin D-sufficient aging population.
The Twist: More Fractures at 1,600 IU?
The 1,600 IU group had a higher fracture risk than placebo (hazard ratio 1.52, 95% CI 1.06–2.18 during supplementation; 1.40, 95% CI 1.08–1.80 over the extended follow-up). That sounds alarming, but the details argue for caution.
- No dose-response. The 3,200 IU group, which took double the dose, showed no meaningful difference from placebo (HR 1.07 and 1.08, with confidence intervals spanning no effect). If vitamin D were driving fractures up, you would expect the higher dose to look worse, not neutral.
- Chance is a real possibility. With fracture counts in the dozens to low hundreds per arm, a modest imbalance can arise by chance, and the confidence interval for the 1,600 IU result runs close to 1.0.
- Subtypes were not significant. No specific fracture type stood out.
The responsible reading is that this trial found no benefit and that the 1,600 IU signal is hard to interpret and may well be a statistical fluke. It is not proof that moderate vitamin D harms bones.
Why Baseline Vitamin D Matters
In a sub-cohort of 550 participants, average baseline serum 25-hydroxyvitamin D was about 74.8 nmol/L, which is already in a sufficient range by commonly used cutoffs. After 12 months, levels were:
- Placebo: 73.0 nmol/L
- 1,600 IU/day: 99.7 nmol/L
- 3,200 IU/day: 120.4 nmol/L
The supplements clearly raised blood levels in a dose-dependent way. Pushing levels well above a healthy baseline did not translate into fewer broken bones. For people who start out sufficient, more may simply not be better.
Limitations to Keep in Mind
- Mostly sufficient population. The results say little about people who are truly deficient, who are the group most likely to benefit from supplementation.
- Fracture counts were modest, which limits the precision of subgroup and subtype analyses.
- Blood levels were measured in only a sub-cohort of 550 people, not in all 2,495 participants.
- Register-based outcomes depend on fractures being recorded in national care databases.
- The trial tested two specific doses and cannot tell us about other regimens, such as intermittent large doses or combinations with other nutrients.
- Funding came mainly from Finnish research councils and foundations. One author reported travel reimbursement from Abiogen Pharma, and others reported involvement in nutrition-recommendation bodies.
Practical Takeaways
The bottom line: if your vitamin D is not low, this trial gives no support for taking high doses to prevent fractures.
- Dose: the study tested 1,600 and 3,200 IU/day, and neither reduced fractures. The trial gives no reason to go higher in pursuit of bone protection, and no reason to assume more is safer or better.
- Test first: a 25-hydroxyvitamin D blood test can show whether you are deficient. Supplementing to correct a documented deficiency is a different question from taking high doses when you are already sufficient.
- Who this applies to: adults roughly 60 and older with adequate vitamin D status who are considering high-dose D mainly for bone protection.
- Who should not rely on it: people with diagnosed deficiency, osteoporosis treatment plans, malabsorption, or other medical conditions. Do not stop prescribed therapy based on one trial; talk to your clinician.
- Don't forget the basics: fracture prevention also depends on fall prevention, strength and balance training, adequate protein and calcium intake, and medical treatment where indicated. These are standard guidance rather than findings of this trial.
The Verdict
FIND adds to a growing body of evidence that vitamin D is not a universal bone shield. For older adults with healthy baseline levels, five years of 1,600 or 3,200 IU daily did not lower fracture risk. The higher fracture count in the 1,600 IU group is a curiosity worth monitoring but, without a dose-response, is not convincing evidence of harm. Check your level, treat a true deficiency, and don't expect megadoses to do more for your skeleton.
